Circulogene

The firm's new RT-PCR assay identifies 20 gene fusion between NTRK1/2/3 and other genes, allowing clinicians to potentially detect rare forms of different cancers.

The deal covers Circulogene's technology for enriching tumor DNA from small volumes of blood for next-generation sequencing-based analysis.

The company's assay relies on proprietary methods of DNA isolation that enable analysis of cell-free DNA from finger-stick volume blood samples.

 

A University of California, Los Angeles-led team has found turning off the CCR5 gene could improve recovery after a stroke, according to Scientific American.

South Dakota lawmakers are to weigh a bill aimed at teaching the strengths and weaknesses of scientific concepts, the Associated Press and KEVN-Black Hills Fox report.

In Science this week: the synthetic genetic system hachimoji, and more.

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.